Premarket Losers as of 9:05 am

• OMED -25% on announcing Phase 2 PINNACLE study assessing tarextumab.
• INCY -10% on FDA's rejection of baricitinib.
• OTCPK:CALI -9%.
• VNCE -8%.
• AKTX -6%.
• LLY -5% on FDA's rejection of baricitinib.